Redox biomarkers in cardiovascularmedicine

Keyvan Karimi Galougahi, Charalambos Antoniades, Stephen J. Nicholls, Keith M. Channon, Gemma A. Figtree

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

The central role of oxidative signalling in cardiovascular pathophysiology positions biometric measures of redox state as excellent markers for research and clinical application.However, despite this tantalizing biological plausibility, no redox biomarker is currently in widespread clinical use. Major recent insights into the mechanistic complexities of redox signalling may yet provide the opportunity to identify markers that most closely reflect the underlying pathobiology. Such redox biomarkers may, in principle, quantify the integrated effects of various known and unknown pathophysiological drivers of cardiovascular disease processes. Recent advances with the greatest potential include assays measuring post-translational oxidative modifications that have significant cellular effects. However, analytical issues, including the relative instability of redox-modified products, remain a major technical obstacle. Appreciation of these challenges may facilitate future development of user-friendly markers with prognostic value in addition to traditional risk factors, and which could be used to guide personalized cardiovascular therapies. We review both established and recently identified biomarkers of redox signalling, and provide a realistic discussion of the many challenges that remain if they are to be incorporated into clinical practice. Despite the current lack of redox biomarkers in clinical application, the integral role of reactive oxygen species in pathogenesis of cardiovascular disease provides a strong incentive for continued efforts.

LanguageEnglish
Pages1576-1582
Number of pages7
JournalEuropean Heart Journal
Volume36
Issue number25
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Biomarker
  • Cardiovascular disease
  • Caveolae
  • Reactive oxygen species
  • Redox signalling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Galougahi, K. K., Antoniades, C., Nicholls, S. J., Channon, K. M., & Figtree, G. A. (2015). Redox biomarkers in cardiovascularmedicine. European Heart Journal, 36(25), 1576-1582. https://doi.org/10.1093/eurheartj/ehv126
Galougahi, Keyvan Karimi ; Antoniades, Charalambos ; Nicholls, Stephen J. ; Channon, Keith M. ; Figtree, Gemma A. / Redox biomarkers in cardiovascularmedicine. In: European Heart Journal. 2015 ; Vol. 36, No. 25. pp. 1576-1582.
@article{dea40b10f2fe47798b7d9b03b03da856,
title = "Redox biomarkers in cardiovascularmedicine",
abstract = "The central role of oxidative signalling in cardiovascular pathophysiology positions biometric measures of redox state as excellent markers for research and clinical application.However, despite this tantalizing biological plausibility, no redox biomarker is currently in widespread clinical use. Major recent insights into the mechanistic complexities of redox signalling may yet provide the opportunity to identify markers that most closely reflect the underlying pathobiology. Such redox biomarkers may, in principle, quantify the integrated effects of various known and unknown pathophysiological drivers of cardiovascular disease processes. Recent advances with the greatest potential include assays measuring post-translational oxidative modifications that have significant cellular effects. However, analytical issues, including the relative instability of redox-modified products, remain a major technical obstacle. Appreciation of these challenges may facilitate future development of user-friendly markers with prognostic value in addition to traditional risk factors, and which could be used to guide personalized cardiovascular therapies. We review both established and recently identified biomarkers of redox signalling, and provide a realistic discussion of the many challenges that remain if they are to be incorporated into clinical practice. Despite the current lack of redox biomarkers in clinical application, the integral role of reactive oxygen species in pathogenesis of cardiovascular disease provides a strong incentive for continued efforts.",
keywords = "Biomarker, Cardiovascular disease, Caveolae, Reactive oxygen species, Redox signalling",
author = "Galougahi, {Keyvan Karimi} and Charalambos Antoniades and Nicholls, {Stephen J.} and Channon, {Keith M.} and Figtree, {Gemma A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/eurheartj/ehv126",
language = "English",
volume = "36",
pages = "1576--1582",
journal = "European heart journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "25",

}

Galougahi, KK, Antoniades, C, Nicholls, SJ, Channon, KM & Figtree, GA 2015, 'Redox biomarkers in cardiovascularmedicine', European Heart Journal, vol. 36, no. 25, pp. 1576-1582. https://doi.org/10.1093/eurheartj/ehv126

Redox biomarkers in cardiovascularmedicine. / Galougahi, Keyvan Karimi; Antoniades, Charalambos; Nicholls, Stephen J.; Channon, Keith M.; Figtree, Gemma A.

In: European Heart Journal, Vol. 36, No. 25, 01.01.2015, p. 1576-1582.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Redox biomarkers in cardiovascularmedicine

AU - Galougahi, Keyvan Karimi

AU - Antoniades, Charalambos

AU - Nicholls, Stephen J.

AU - Channon, Keith M.

AU - Figtree, Gemma A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The central role of oxidative signalling in cardiovascular pathophysiology positions biometric measures of redox state as excellent markers for research and clinical application.However, despite this tantalizing biological plausibility, no redox biomarker is currently in widespread clinical use. Major recent insights into the mechanistic complexities of redox signalling may yet provide the opportunity to identify markers that most closely reflect the underlying pathobiology. Such redox biomarkers may, in principle, quantify the integrated effects of various known and unknown pathophysiological drivers of cardiovascular disease processes. Recent advances with the greatest potential include assays measuring post-translational oxidative modifications that have significant cellular effects. However, analytical issues, including the relative instability of redox-modified products, remain a major technical obstacle. Appreciation of these challenges may facilitate future development of user-friendly markers with prognostic value in addition to traditional risk factors, and which could be used to guide personalized cardiovascular therapies. We review both established and recently identified biomarkers of redox signalling, and provide a realistic discussion of the many challenges that remain if they are to be incorporated into clinical practice. Despite the current lack of redox biomarkers in clinical application, the integral role of reactive oxygen species in pathogenesis of cardiovascular disease provides a strong incentive for continued efforts.

AB - The central role of oxidative signalling in cardiovascular pathophysiology positions biometric measures of redox state as excellent markers for research and clinical application.However, despite this tantalizing biological plausibility, no redox biomarker is currently in widespread clinical use. Major recent insights into the mechanistic complexities of redox signalling may yet provide the opportunity to identify markers that most closely reflect the underlying pathobiology. Such redox biomarkers may, in principle, quantify the integrated effects of various known and unknown pathophysiological drivers of cardiovascular disease processes. Recent advances with the greatest potential include assays measuring post-translational oxidative modifications that have significant cellular effects. However, analytical issues, including the relative instability of redox-modified products, remain a major technical obstacle. Appreciation of these challenges may facilitate future development of user-friendly markers with prognostic value in addition to traditional risk factors, and which could be used to guide personalized cardiovascular therapies. We review both established and recently identified biomarkers of redox signalling, and provide a realistic discussion of the many challenges that remain if they are to be incorporated into clinical practice. Despite the current lack of redox biomarkers in clinical application, the integral role of reactive oxygen species in pathogenesis of cardiovascular disease provides a strong incentive for continued efforts.

KW - Biomarker

KW - Cardiovascular disease

KW - Caveolae

KW - Reactive oxygen species

KW - Redox signalling

UR - http://www.scopus.com/inward/record.url?scp=84942430256&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehv126

DO - 10.1093/eurheartj/ehv126

M3 - Review article

VL - 36

SP - 1576

EP - 1582

JO - European heart journal

T2 - European heart journal

JF - European heart journal

SN - 0195-668X

IS - 25

ER -

Galougahi KK, Antoniades C, Nicholls SJ, Channon KM, Figtree GA. Redox biomarkers in cardiovascularmedicine. European Heart Journal. 2015 Jan 1;36(25):1576-1582. https://doi.org/10.1093/eurheartj/ehv126